CONTROVERSIES IN CARDIOVASCULAR MEDICINE (Pro) Intensive Lipid-Lowering in CAD
the Cholesterol Treatment Trialists Collaborators (CTTC) 9 of 90,056 patients from 14 prospective clinical trials during a mean of 5 years, lowering the LDL-C level by 1 mmol/L (=39 mg/dl) was found to reduce total mortality by 19%, coronary events by 23%, and cardiac events by 21%, except for cerebral hemorrhage ( Figure 1A ). Thus, in order to reduce cardiac events by 1%, it is necessary to lower the LDL-C level by 1.8 mg/dl ( Figure 1B ). More importantly, that analysis showed that clinical benefit was linearly related to the absolute reduction in LDL-C.
Outcome Studies of Intensive Lipid-Lowering Therapy Using Statins

MIRACL (Myocardial Ischemia Reduction With Aggressive
Cholesterol Lowering) was the first outcome study to demonstrate the efficacy of high-dose statin therapy. 10 That study compared high-dose atorvastatin (80 mg) and a placebo administered during the 24-to 96-h period after an episode of unstable angina or non-Q wave myocardial infarction (MI).
The combination endpoint of death, non-fatal MI, cardiac Relationship between proportional reduction in the incidence of major coronary events (Left) and major vascular events (Right) and mean absolute LDL-C at 1 year. There is a linear correlation between LDL-C reduction and cardiovascular events. CI, confidence interval; LDL-C, low-density lipoprotein cholesterol; MI, myocardial infarction; RR, relative risk. Reference 9.
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arrest with resuscitation or worsening symptomatic myocardial ischemia were significantly reduced by atorvastatin over a 16-week treatment. In addition, the PROVE-IT (Pravastatin or Atorvastatin Evaluation and Infection Therapy Thrombolysis in Myocardial Infarction) study assessed whether more aggressive LDL-C lowering therapy with higher doses of more potent statins was able to show clinical efficacy superior to that with high doses of less potent statins. 11 Briefly, 4,162 patients with acute coronary syndrome (ACS) within the preceding 10 days were randomized to atorvastatin 80 mg/day or pravastatin 40 mg/day. The mean observation period was 24 months, and the primary endpoints were death, MI, unstable angina requiring rehospitalization, revascularization (at least 30 days after randomization), and stroke. The primary endpoint was 22.4% in the atorvastatin group and 26.3% in the pravastatin group (hazard ratio (HR): 0.84, confidence interval (CI): 0.74-0.95, P=0.005). The benefit of high-dose atorvastatin as compared with high-dose pravastatin emerged as early as 30 days and was consistent over time.
The PROVE-IT trial examined intensive vs moderate statin therapy after ACS and concluded an early benefit for intensive therapy. The results of the PROVE-IT trial are particularly noteworthy because the comparator was treated with pravastatin 40 mg/day, the drug and dose that significantly reduced the primary endpoint in 4 previous large clinical trials. Furthermore, early initiation of treatment provided near immediate benefit. It was thus the meta-analyses that compiled the effects of intensive lipid-lowering therapy, and a recent report showed that intensive lipid-lowering therapy using a high-dose statin improved the prognosis of cardiac events (Table 2 ). In a meta-analysis of 4 large-scale clinical studies (PROVE-IT 11 , A-to-Z 12 , TNT 13 and IDEAL 14 ) that tested statins against each other and compared cardiac events in a standard therapy group with an LDL-C target of 100 mg/dl and an intensivetherapy group with an LDL-C target of 70-80 mg/dl, the analyzed patients numbered 27,548, and the percent reduction in the LDL-C value was 22% in the standard therapy group vs 42% in the intensive therapy group. 15 For coronary death and MI, the odds ratio in the intensive therapy group vs the standard therapy group was 0.84 (95%CI: 0.77-0.91; P=0.00003), and that for cerebrovascular events was 0.82 (95%CI: 0.71-0.96; P=0.012), with both representing a significant decrease. In addition, in a meta-analysis that included only ACS patients, 16 high-dose statin therapy that was started early (within 14 days after hospitalization) was shown to be effective in 17,963 patients enrolled in 13 prospective clinical studies. For death and cardiac events occurring within 2 years, the HR was 0.81 with high-dose statin therapy vs standard therapy (P<0.001), and the reduction in mortality started within 4-12 months, with a statistically significant difference observed after 1 year. 17 In addition, between 1996 and 2006, 6 prospective studies involving 110,271 patients investigated the significance of intensive lipid-lowering therapy in relation to ischemic heart disease, and a meta-analysis 17 showed that this type of therapy was effective in relation to all events in ACS, including death. Moreover, although no decrease in the mortality rate was observed relative to the stable CAD form of ACS, cardiac events were significantly reduced. In those studies, however, warnings were raised (Pro) Intensive Lipid-Lowering in CAD with regard to hepatic dysfunction and significant elevation creatine phosphokinase with high-dose statin therapy. However, the positive association between absolute reduction of LDL-C and major cardiovascular events suggests that a large reduction in LDL-C produces a greater reduction in adverse events. Therefore, the optimal goal of less than 70 mg/dl has become the standard not only for patients at very high risk, but for patients with CAD in Europe and the United States. MIYAUCHI K et al.
Do Statins Cause Regression of Coronary Plaque?
The clinical issue arose of whether LDL-C reduction through statin therapy retarded progression of coronary artery plaque. The development of intravascular ultrasound (IVUS) enabled measurement of the volume of coronary artery plaque, allowing us to determine the percent change in this parameter before and after medical intervention. The REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid Lowering) trial 18 was a landmark statin intervention trial that investigated whether the reduction of LDL-C by statins attenuated the progression of coronary artery plaque in patient with CAD. A total of 654 patients were randomized into 2 groups, administered either atorvastatin 80 mg (LDL-C ≤79 mg/dl) or pravastatin 40 mg (LDL-C ≤100 mg/dl), and the change in coronary plaque volume on IVUS after 18 months of treatment was compared between the groups. Although an increase in plaque volume was observed in the pravastatin group, the atorvastatin group halted plaque progression (% change in plaque volume: 2.7% vs −0.4%). This finding thus demonstrated that intensive lipid-lowering therapy using a atorvastatin attenuated plaque progression. In addition, the ASTEROID (A Study to Evaluate the Effect of Rosuvastatin on Intravascular UltrasoundDerived Coronary Atheroma Burden) 19 study first demonstrated that rosuvastatin 40 mg treatment for 24 months to average LDL-C levels well below 70 mg/dl produced plaque regression by 15% in CAD patients. That was a single-arm study, but the it unexpectedly found a remarkable reduction of LDL-C and an increase in the high-density lipoproteincholesterol (HDL-C) level. Therefore, REVERSAL demonstrated that atorvastatin 80 mg halted plaque progression, but there was not regression, whereas there was actual regression at least on average in ASTEROID.
The published data regarding the correlation between lipidlowering therapy and plaque regression in Japan is summarized in Table 3 . An IVUS assessment for patients with ACS was conducted in the ESTABLISH (Early Statin Treatment in Patients with Acute Coronary Syndrome) study, 20 which was the first to demonstrate that intensive lipid-lowering therapy with atorvastatin led to a significant plaque regression in Japanese ACS patients. Briefly, 70 ACS patients who had undergone successful percutaneous coronary intervention (PCI) were randomized into an intensive lipid-lowering therapy group (atorvastatin 20 mg/day) and a control group. IVUS was performed at baseline and after 6 months of treatment, and the plaque volume was measured in the non-PCI site. Figure 2 presents the results: the reduction in LDL-C was 41.7% in the atorvastatin group and plaque volume was reduced by 13%, whereas in the control group plaque volume increased by 8%. The percent change in plaque volume correlated positively with the percent decrease in LDL-C, and it was demonstrated that the greater the decrease in LDL-C, the greater the plaque regression. This tendency was observed regardless of the baseline LDL-C level, and it was thus surmised that plaque regression by aggressive LDL-C lowering could be attributed to the acute effect of statins in ACS, independent of the baseline LDL-C level. The limitations of the ESTABLISH trial were that it was a relatively small trial conducted at a single center. Therefore, the JAPAN-ACS (Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome) study was designed as a large-scale, multicenter trial to overcome those flaws. 21 The JAPAN-ACS study was the world's first head-to-head trial between pitavastatin 4 mg and atorvastatin 20 mg. The results showed no differences between the 2 groups in either the percent decrease in LDL-C (36.2% vs 35.8%) or the percent plaque regression (17% vs 18%) over the 10-month observation period, and it was demonstrated that both statins showed (Pro) Intensive Lipid-Lowering in CAD equivalent plaque-regression effects. At the same time, it was confirmed that the marked efficacy of high-dose statin therapy in bringing about plaque regression was also seen in Japanese patients. However, this study did not find any correlation between LDL-C reduction and plaque regression, and it differed from the ESTABLISH study, which included a control group (Figure 3 ). However, this was not surprising because JAPAN-ACS did not have a placebo arm that was no lipid-lowering therapy. The scattergrams were obtained from the cluster with groups exclusively on intensive statin therapy. It was considered that other factors were also responsible for the plaque regression. The impressive result was that the administration of the statins used over 10 months caused a net reduction of plaque volume in 88% of patients with ACS, even at a mean LDL-C level of 82.6 mg/dl. This suggested that pitavastatin, as well as atorvastatin itself, might play a specific role in the regression of atherosclerosis in patients with ACS, not only by a reduction of the LDL-C level. The COSMOS (Coronary Atherosclerosis Study Measuring Effects of Rosuvastatin Using Intravascular Ultrasound in Japanese Subjects) study 22 demonstrated that rosuvastatin shows plaque-regression effects in stable CAD patients in Japan. In that study, rosuvastatin was not administered in a fixed dose: the protocol called for dose escalation if the LDL-C level reached 80 mg/dl, and the final mean dose of rosuvastatin was 17 mg/day. The COSMOS study was a single-arm study, with no control group and only a single statin group. The LDL-C level was reduced by 39% from 140.2 mg/dl to 82.9 mg/dl, and IVUS performed after an 18-month observation period showed that the plaque regression rate was 5%, which was statistically significant. When all of the different IVUS studies were examined by plotting LDL-C values against the change in atheroma volume, a relationship between mean LDL-C level and median change in percent atheroma volume was observed (Figure 4) . Linear regression analysis showed that the mean plaque progression rate correlated with the mean LDL-C level, despite the known limitations of cross-trial comparisons. When viewed in this context, there exists no apparent threshold LDL-C level beyond which the benefits of statin therapy are no longer evident. If regression of the disease is the desired outcome, then lower LDL-C is better.
Several clinical trials have investigated by IVUS the beneficial effect of statin treatment on plaque regression; however, the impact of plaque regression on clinical outcomes in patient with CAD has not been defined. Nicholls et al 23 reported that coronary plaque progression was evaluated in 4,137 patients in 6 clinical trials that used serial IVUS to clarify the relationship between the extent and progression of coronary atherosclerosis and the subsequent risk for adverse cardiovascular outcomes. In their meta-analysis, plaque volume increased by 0.3%, and 19.9% of subjects experienced major adverse cardiovascular event (MACE: death, MI, revascularization). Each standard deviation increase in plaque volume was associated with a 1.32-fold (95%CI: 1.22-1.42; P<0.001) greater likelihood of experiencing MACE. During follow-up (21.1±3.7 months), greater increases in plaque volume were observed in subjects who experienced MACE compared with those who did not (0.95±0.19% vs 0.46±0.16%, P<0.001). Thus, plaque regression may be sufficient to produce a clinical benefit, even though the absolute amount of regression achieved is small. These findings imply that plaque regression could be a realistic goal, because plaque regression on volumetric IVUS is associated with better long-term clinical outcomes. . Relationship between mean low-density lipoprotein cholesterol (LDL-C) levels and mean percent change in plaque volume in several intravascular ultrasound trials. Each study is represented with drug examined, countries and type of coronary disease. In the ASTEROID trial, the percent change in normalized total plaque volume was used instead of the percent change in plaque volume because data could not be directly obtained. However, the value should be mathematically identical. Reference 19.
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Can Intensive Lipid-Lowering Therapy Using
Statins Bring About Qualitative Changes in Plaque?
Stabilization of plaque is considered the major contributor to reducing cardiovascular events, and identification of vulnerable plaque has great clinical implication. Imaging techniques to detect qualitative changes in coronary artery walls, including coronary angioscopy (CAS), optical coherence tomography (OCT) using infrared rays, magnetic resonance imaging (MRI), and IVUS, have significantly developed and advanced in recent years. These tools offer the potential for quantitative tissue characterization of the coronary arterial wall. Application of these imaging techniques also allows us to monitor qualitative improvements in response to pharmaceutical interventions.
In the CPLASS (Coronary PLAque stabilization by Statin Study), 24 the integrated backscatter (IB) value of IB-IVUS was used as the endpoint to compare an atorvastatin 10 mg group and a control group over a 6-month period. The results showed that the IB value increased depending on the percent decrease in LDL-C; that is, the plaque stabilized. In particular, significant plaque stabilization occurred when LDL-C was decreased by 50% or more. Takano et al 25 evaluated plaque quality using CAS after statin treatment in 31 stable CAD patients who were randomized into an atorvastatin group and a control group and followed for 12 months. Angioscopy was used to evaluate 145 sites on the basis of 4 grades of plaque color (yellow to white), and in the statin group LDL-C was reduced by 45%, the plaque color score changed from 2.03 to 1.13 (ie, from yellow to white), and the plaque color score decreased according to the reduction in the LDL-C concentration. Takarada et al 26 carried out research using OCT during statin intervention for 9 months after ST elevation MI (STEMI). The fibrous-cap thickness was compared between a 23-patient statin group that was administered a statin and 17 control patients. LDL-C was reduced in the statin group from 144 to 91 mg/dl, and the fibrous-cap thickness was significantly increased at 188% compared with 117% in the control group, thus indicating plaque stabilization. Toi et al 27 used virtual histology (VH) IVUS to evaluate the short-term effect of high-dose statin therapy on plaque properties in the acute stage of ACS in 160 patients. When pitavastatin 2 mg and atorvastatin 10 mg were administered for 2-3 weeks, the plaque volume decreased significantly by 2.6% in the pitavastatin group accompanied by a significant decrease in the fibrofatty component. On the other hand, in the atorvastatin group, there were no changes in either the plaque volume or the tissue characteristics. No consensus has yet been reached regarding the evaluation of plaque properties by VH-IVUS, but this technique has indicated the possibility of differences in the short-term effects of different drugs on plaque properties. The statin-intervention studies noted thus far have demonstrated that statin administration has various favorable effects, including plaque stabilization and especially reduction of the lipid pool and an increase in the thin fibrous cap. These plaque stabilization studies were summarized in Table 4 .
In addition, Hirayama et al 28 carried out clinical research aimed at elucidating the processes by which statins beneficially alter the volume and quality of plaque. Their study design consisted of administering atorvastatin 10-20 mg to stable CAD patients and then observing the plaque quality and volume over time. Both IVUS and CAS were performed after 6 and 18 months of treatment, and the plaque quality and volume were assessed. Angioscopy showed that the plaque color had already changed from yellow to white at the 6-month point, indicating stabilization, and this remained unchanged after 18 months. However, the plaque volume continually decreased during the period from 6 to 18 months. Accordingly, this research demonstrated that statin therapy leads to qualitative improvement in plaque during the early stage of medication and that quantitative improvement continues during the long-term.
Pleiotropic and Anti-Inflammatory Effects of Statins
Many clinical studies have demonstrated that statins reduce hs-C-reactive protein (hs-CRP). 29, 30 The REVERSAL trial showed that high-dose statin therapy lowers hs-CRP even more than standard statin therapy. 31 Moreover, it has also been demonstrated that there is an increase in cardiac events, regardless of primary or secondary prevention, when the hs-CRP level is high, and that lowering the hs-CRP concentration by statin therapy reduces the number of cardiac events. 32, 33 In light of those results, it was realized that hs-CRP is also an important clinical marker, and at the same time attention was drawn to the role of inflammation in the mechanism by which statins reduce clinical events.
The importance of inhibition of inflammation in tissues is clear from the fact that inflammation is involved in vulnerable plaque, and it was surmised that the possibility that statins 24 Takano et al 25 Takarada et al 26 Toi et al 27 Imaging 
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inhibit inflammation in tissues is also clinically important. In that context, we carried out a clinical study aimed at confirming the anti-inflammatory effect of a statin in the tissues of patients with an abdominal aortic aneurysm (AAA). 34 This was a prospective clinical study conducted in 20 AAA patients scheduled to undergo surgery, who were randomized into a group orally administered atorvastatin 20 mg and a control group, consisting of 10 patients each. Tissue specimens were obtained from each patient at the time of surgery, and the inflammatory tissue findings were compared between the groups. The time interval between initiation of atorvastatin administration and surgery was approximately 1 month. Figure 5 compares the findings in the 2 groups: the numbers of inflammatory cells, macrophages, dendritic cells, and T cells were all reduced in the atorvastatin group compared with the control group. Quantitatively, as well, the inhibitory effect was approximately 50% and statistically significant. Accordingly, these results demonstrate that even short-term administration of a statin can inhibit tissue inflammation.
In addition, the anti-inflammatory effect of statins was (Pro) Intensive Lipid-Lowering in CAD studied in a porcine coronary artery stent model with the objective of proving the hypothesis that increasing the statin concentration can more potently inhibit tissue inflammation. Thus, the tissue concentration of a statin was elevated locally by insertion of a statin-eluting stent, 35 and inflammatory cell adhesion in the tissue was used as the endpoint and evaluated for correlation with the statin tissue concentration. On the 3 rd day after bare-metal stent implantation in the porcine coronary artery, monocyte adhesion to the stent surface was observed by electron microscopy. Figure 6 shows that cell adhesion was significantly inhibited by local statin administration compared with systemic dosing. Accordingly, this study proved that the anti-inflammatory effect of a statin is further increased when the local statin concentration is elevated. Furthermore, we evaluated neointimal hyperplasia 28 days after stenting.
In our results, large reductions in the early inflammatory response produce greater inhibition of late neointima as shown in Figure 6B . Thus, clinical and experimental data suggest the importance of the anti-inflammatory effect by statins as a contributor to plaque stabilization, plaque regression, and reduction in clinical events. Inhibition of inflammation in tissues is important, but serious limitations exist regarding the evaluation methods because our ability to examine inflammation is currently restricted to using tissue sections, not in vivo clinical imaging. However, in recent years, progress in molecular imaging techniques has enabled us to assess the extent of inflammation in vivo by means of MRI. 36 Furthermore, fluorodeoxyglucose (FDG) with positron emission tomography (PET) is a molecular imaging technique that is highly sensitive to metabolically active processes using glucose as a fuel. Recently, arterial FDG PET imaging has been suggested as a biomarker for reporting on the metabolic activity of atherosclerosis. 37 It is thus anticipated that, in the future, imaging diagnosis will have a role in monitoring the response of atherosclerosis, especially vulnerable plaque stabilization, to statin therapy.
Issues Associated With Statin Therapy
Even in routine medical clinical practice, we encounter ACS patients with a low LDL level of less than 80 mg/dl, and we are concerned about whether we should prescribe statins to these patients. The large-scale clinical trials that have been carried out to date have not clarified the pluses and minuses of administering lipid-lowering statin therapy to low-LDL patients because none of these trials have taken into account the pretreatment LDL level. However, an observational study of ACS patients compared the prognosis (mortality, re-infarction, and stroke) over a 6-month period in patients with an LDL level of less than 80 mg/dl based on whether or not a statin was administered at the time of discharge from hospital. 38 The incidence of events in the statin-treated group was 9.5%, which was significantly lower than the 29% incidence reported for the untreated group. Furthermore, a meta-analy- 
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sis has provides useful insights into the issues of threshold and target levels by documenting the multivariate relationship of clinical outcome to baseline LDL and magnitude of LDL reduction. 39 That study showed a graded relationship of treatment benefit according to tertiles of baseline LDL (from <70 to >100 mg/dl) and quartiles of percent LDL lowering (from <10% to >30%), which analysis demonstrated there is great clinical benefit to lowering the LDL level in patients with a high LDL-C level prior to intervention, although it has become increasingly clear that this benefit is also seen in patients with a low LDL level.
For the very-high-risk group of patients, such as those with ACS, the ACC/AHA guidelines have set a value of less than 70 mg/dl as the therapeutic target for LDL-C, but that does not mean that all issues have been resolved. In each of the clinical trials that studied ACS patients, including the PROVE-IT and A-to-Z trials, the statin dosage was fixed, and the design did not provide for adjustment of the administered dose toward the therapeutic target for LDL-C. In other words, rather than the LDL-C value, the statin dose or type becomes important. In particular, in studies that compare statins, there is a possibility that differences in the pleiotropic effects of statins (eg, anti-inflammatory activity, improvement in endothelial function, reduction of oxidative stress, and antithrombotic activity) come into play. In consideration of this background, European Society of Cardiology guideline the administration criteria for statins in the treatment of ACS recommended are within the early (1-4 day) period after onset, with an LDL target of less than 100 mg/dl (Class I, Evidence Level B), and intensive statin lipid-lowering therapy with an LDL target of less than 70 mg/dl (Class IIa, Evidence Level B) within 10 days of hospitalization.
Evidence and Issues Associated With Secondary Prevention Using Statins in Japanese
As an observational study performed to date, our ESTABLISH study was increased to a patient total of 180 and reported as the Extended-ESTABLISH study ( Figure 7A ). 40 This study followed the atorvastatin group and control group for 6 months, after which a statin was administered to all of the patients and subsequent events, including death, ACS, and stroke, were evaluated. Evaluation was performed regarding whether early administration of a statin influenced subsequent events, and it was found that the prognosis was significantly improved in the early statin administration group ( Figure 7B ). 42 is the only prospective clinical study that investigated ACS and their results showed that reduction of the LDL-C level to at least 100 mg/dl by a statin reduced the number of cardiac events. However, we do not have a prospective clinical trial to test whether intensification of statin therapy based on achieving LDL-C levels would improve clinical outcomes in Japan similar to those in Europe and the United States. At present there have not even been any studies in Japan that have provided a rationale for a value such as 100 mg/dl for the LDL-C concentration and the beneficial effects occur regardless of the baseline LDL-C level and risk factors. The REAL-CAD (Randomized Evaluation of Aggressive or Moderate Lipid Lowering Therapy with Pitavastatin in Coronary Artery Disease multicenter, prospective, large-scale clinical study) (NCT01042730, UMIN000002680) is being carried out in an attempt to answer these issues in Japan (Figure 8 ). Stable CAD patients are randomized into pitavastatin 1 mg and 4 mg groups and then followed-up for 3 years in regard to primary endpoints consisting of cardiovascular death, non-fatal MI, non-fatal cerebral infarction, and unstable angina pectoris (Pro) Intensive Lipid-Lowering in CAD requiring emergency hospitalization. It was estimated that a difference of 20 mg/dl in the LDL-C level between the 2 dosage groups during follow-up would represent an approximately 16% reduction in the relative risk, and that the annual incidence of events in Japan will be approximately 2.5%. It was then calculated that 12,600 patients will be needed for the analyses. When the study results are reported after 5 years, we will have categorical evidence regarding the effects of statins in Japan. The optimal statin dose, as well as the target LDL-C concentration for secondary prevention in Japanese patients, will have been clarified. It can be surmised that these results will effect future Japanese treatment guidelines.
Conclusions
Large-scale clinical trials and meta-analyses have clarified that intensive lipid-lowering therapy using statins is useful for bringing about stabilization and regression of plaque, as well as inhibiting adverse cardiovascular events. As a result, the American College of Cardiology has established an LDL-C target value of 70 mg/dl for secondary prevention. Still, various issues remain, including when statin therapy should be initiated, which statin should be administered, what the appropriate statin dosage is, and how long medication should be continued. In Japan, we still lack evidence that, as secondary prevention, events are decreased by intensive lipid-lowering therapy using statins. We are very hopeful that the results of the large-scale clinical trials that are currently in progress in Japan will resolve this issue.
